NCT03207750: A reported trial by GlaxoSmithKline
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03207750 |
|---|---|
| Title | Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 14, 2017 |
| Completion date | Oct. 9, 2018 |
| Required reporting date | Oct. 9, 2019, midnight |
| Actual reporting date | Oct. 8, 2019 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |